Explore the vast range of titles available.

The rising number of fungal infections has prompted the need to understand every aspect of pathogenic fungi, which are capable of infecting humans, animals and insects. This exhaustive book meets that crucial need.

\"A prescient warning about the mysterious and deadly world of fungi-and how to avert further loss across species, including our own. Fungi are everywhere. Most are harmless; some are helpful. A few are killers. Collectively, infectious fungi are the most devastating agents of disease on earth, and a fungus that can persist in the environment without its host is here to stay. In Blight, Emily Monosson documents how trade, travel, and a changing climate are making us all more vulnerable to invasion. Populations of bats, frogs, and salamanders face extinction. In the Northwest, America's beloved national parks are covered with the spindly corpses of whitebark pines. Food crops are under siege, threatening our coffee, bananas, and wheat-and, more broadly, our global food security. Candida auris, drug-resistant and resilient, infects hospital patients and those with weakened immune systems. Coccidioides, which lives in drier dusty regions, may cause infection in apparently healthy people. The horrors go on. Yet prevention is not impossible. Tracing the history of fungal spread and the most recent discoveries in the field, Monosson meets scientists who are working tirelessly to protect species under threat, and whose innovative approaches to fungal invasion have the potential to save human lives. Delving into case studies at once fascinating, sobering, and hopeful, Blight serves as a wake-up call, a reminder of the delicate interconnectedness of the natural world, and a lesson in seeing life on our planet with renewed humility and awe\"-- Provided by publisher.

\"From beneficial fungi that keep bacteria under control and consume dead cells to toxic molds that cause disease, our bodies are constantly navigating a fungus-filled world. And our interactions with fungi are not limited to what happens in our bodies as we interact with these microbes via our diet and as a source of medicines. In short, there exists an incredible range of interactions between humans and fungi. In this book, Nicolas Money describes this relationship between fungi and humans in the context of our health. Readers learn how the field of mycology has been advancing, from studies that reveal the diversity of yeasts that grow on the skin to research on the use of psychedelic mushrooms in the treatment of depression. The book is divided into two parts. The first part focuses on how fungi operate in our bodies from spores in the lungs to the yeasts and filaments that can infect our internal organs. In particular, Money focuses on the mycobiome, which is the fungal part of the larger microbiome, and explains what is and isn't known about the significance of fungi in the health of the gut. In the second half of the book, Money shifts his focus to our relationship with fungi outside the body, including in food, medicine, and agriculture -- and he pulls no punches when it comes to countering misguided notions when it comes to the medicinal powers of mushrooms. Throughout the book, Money explains how the human-fungi relationship is symbiotic, meaning that it is sometimes beneficial and sometimes harmful. Ultimately, the reader comes away with a broad understanding of what scientists are learning about the fascinating role of fungi inside and outside of our bodies\"-- Provided by publisher.

and are important causative agents of superficial mycoses, demonstrating emergent antifungal drug resistance. We studied the antifungal susceptibility profiles in Iranian isolates of these two species. A total of 96 and 45 isolates were subjected to molecular typing by ribosomal ITS region. Antifungal susceptibility profiles for terbinafine, griseofulvin, clotrimazole, efinaconazole, luliconazole, amorolfine and ciclopirox were obtained by CLSI broth microdilution method. The squalene epoxidase ( ) gene was subjected to sequencing for mutations, if any, in isolates exhibiting elevated MICs for terbinafine. Luliconazole and efinaconazole showed the lowest MIC values against and isolates. There were five isolates with terbinafine MICs ≥32 µg/mL in our sample. They belonged to type VIII and harbored two alternative gene sequence variants, leading to Phe397Leu and Ala448Thr or Leu393Ser and Ala448Thr substitutions in the enzyme. All terbinafine resistant strains could be inhibited by luliconazole and efinaconazole. This study documented a step in the global spread of resistance mechanisms in . However, treatment alternatives for resistant isolates were available.

The epidemiology of invasive fungal diseases (IFDs) is hard to delineate given the difficulties in ascertaining the diagnosis that is often based on the confrontation of clinical and microbiological criteria. The present report underlines the interest of active surveillance involving mycologists and clinicians to describe the global incidence and that of the main IFDs. The French National Reference Center for Invasive Mycoses and Antifungals leads an active and sustained nationwide surveillance program on probable and proven invasive fungal diseases (IFDs) to determine their epidemiology in France. Between 2012 and 2018, a total of 10,886 IFDs were recorded. The incidence increased slightly over time (2.16 to 2.36/10,000 hospitalization days, P  = 0.0562) in relation with an increase of fungemia incidence (1.03 to 1.19/10,000, P  = 0.0023), while that of other IFDs remained stable. The proportion of ≥65-year-old patients increased from 38.4% to 45.3% ( P  < 0.0001). Yeast fungemia ( n  = 5,444) was due mainly to Candida albicans (55.6%) with stable proportions of species over time. Echinocandins became the main drug prescribed (46.7% to 61.8%), but global mortality rate remained unchanged (36.3% at 1 month). Pneumocystis jirovecii pneumonia ( n  = 2,106) was diagnosed mostly in HIV-negative patients (80.7%) with a significantly higher mortality than in HIV-positive patients (21.9% versus 5.4% at 1 month, P  < 0.0001). Invasive aspergillosis ( n  = 1,661) and mucormycosis ( n  = 314) were diagnosed mostly in hematology (>60% of the cases) with a global mortality rate of 42.5% and 59.3%, respectively, at 3 months and significant changes in diagnosis procedure over time. More concurrent infections were also diagnosed over time (from 5.4% to 9.4% for mold IFDs, P  = 0.0115). In conclusion, we observed an aging of patients with IFD with a significant increase in incidence only for yeast fungemia, a trend toward more concurrent infections, which raises diagnostic and therapeutic issues. Overall, global survival associated with IFDs has not improved despite updated guidelines and new diagnostic tools. IMPORTANCE The epidemiology of invasive fungal diseases (IFDs) is hard to delineate given the difficulties in ascertaining the diagnosis that is often based on the confrontation of clinical and microbiological criteria. The present report underlines the interest of active surveillance involving mycologists and clinicians to describe the global incidence and that of the main IFDs. Globally, although the incidence of Pneumocystis pneumonia, invasive aspergillosis, and mucormycosis remained stable over the study period (2012 to 2018), that of yeast fungemia increased slightly. We also show here that IFDs seem to affect older people more frequently. The most worrisome observation is the lack of improvement in the global survival rate associated with IFDs despite the increasing use of more sensitive diagnostic tools, the availability of new antifungal drugs very active in clinical trials, and a still low/marginal rate of acquired in vitro resistance in France. Therefore, other tracks of improvement should be investigated actively.

Fungal entomopathogens have been proposed as environmentally friendly alternatives to chemical control. Unfortunately, their effectiveness continues to be limited by their susceptibility to ultraviolet (UV) light and low moisture. A relatively recent development, the use of fungal entomopathogens as endophytes, might overcome the traditional obstacles impeding the widespread adoption of fungal entomopathogens and also provide a novel alternative for management of insect pests and plant pathogens. In addition, some fungal entomopathogens could also function as biofertilizers. Eighty-five papers covering 109 individual fungal entomopathogen studies involving 12 species in six genera are reviewed. Thirty-eight plant species in 19 families were studied, with maize, common bean, and tomato being the most investigated. Of the 85 papers, 39 (46%) examined the effects of fungal entomopathogen endophytism on 33 insect species in 17 families and eight orders. Thirty-four (40%) examined plant response to endophytism, corresponding to 20 plant species. Various inoculation techniques (e.g., foliar sprays, soil drenching, seed soaking, injections, etc.) are effective in introducing fungal entomopathogens as endophytes, but colonization appears to be localized and ephemeral. The field of insect pathology will not substantially profit from dozens of additional studies attempting to introduce fungal entomopathogens into a wider array of plants, without attempting to understand the mechanisms underlying endophytism, the responses of the plant to such endophytism, and the consequent responses of insect pests and plant pathogens. This review presents several areas that should receive focused attention to increase the probability of success for making this technology an effective alternative to chemical control.

Mucormycosis is an angioinvasive fungal infection, due to fungi of the order Mucorales. Its incidence cannot be measured exactly, since there are few population-based studies, but multiple studies have shown that it is increasing. The prevalence of mucormycosis in India is about 80 times the prevalence in developed countries, being approximately 0.14 cases per 1000 population. Diabetes mellitus is the main underlying disease globally, especially in low and middle-income countries. In developed countries the most common underlying diseases are hematological malignancies and transplantation. Τhe epidemiology of mucormycosis is evolving as new immunomodulating agents are used in the treatment of cancer and autoimmune diseases, and as the modern diagnostic tools lead to the identification of previously uncommon genera/species such as Apophysomyces or Saksenaea complex. In addition, new risk factors are reported from Asia, including post-pulmonary tuberculosis and chronic kidney disease. New emerging species include Rhizopus homothallicus, Thamnostylum lucknowense, Mucor irregularis and Saksenaea erythrospora. Diagnosis of mucormycosis remains challenging. Clinical approach to diagnosis has a low sensitivity and specificity, it helps however in raising suspicion and prompting the initiation of laboratory testing. Histopathology, direct examination and culture remain essential tools, although the molecular methods are improving. The internal transcribed spacer (ITS) region is the most widely sequenced DNA region for fungi and it is recommended as a first-line method for species identification of Mucorales. New molecular platforms are being investigated and new fungal genetic targets are being explored. Molecular-based methods have gained acceptance for confirmation of the infection when applied on tissues. Methods on the detection of Mucorales DNA in blood have shown promising results for earlier and rapid diagnosis and could be used as screening tests in high-risk patients, but have to be validated in clinical studies. More, much needed, rapid methods that do not require invasive procedures, such as serology-based point-of-care, or metabolomics-based breath tests, are being developed and hopefully will be evaluated in the near future.